Lorundrostat (MLS-101)

About Mineralys Therapeutics

Mineralys Therapeutics is focused on developing targeted therapies for cardio-renal-metabolic syndrome (CRMS), beginning with treatment-resistant hypertension (TRH). The company's core achievement is the in-licensing and clinical validation of lorundrostat, a selective aldosterone synthase inhibitor, which demonstrated compelling proof-of-concept in a Phase 2 study. Its strategy is to become the first mover in a novel drug class, targeting the estimated 30% of hypertensive patients with dysregulated aldosterone, while building a lean, digitally-enabled organization for efficient development and future commercialization.

About Mineralys Therapeutics

Mineralys Therapeutics is focused on developing targeted therapies for cardio-renal-metabolic syndrome (CRMS), beginning with treatment-resistant hypertension (TRH). The company's core achievement is the in-licensing and clinical validation of lorundrostat, a selective aldosterone synthase inhibitor, which demonstrated compelling proof-of-concept in a Phase 2 study. Its strategy is to become the first mover in a novel drug class, targeting the estimated 30% of hypertensive patients with dysregulated aldosterone, while building a lean, digitally-enabled organization for efficient development and future commercialization.

Therapeutic Areas